Abstract:Background: P38α is a ubiquitous protein kinase, which plays diverse roles in cancers. Surprisingly, P38α functions vary markedly in different cancers (e.g., cancer suppressor vs cancer promoter). However, there is no report on the expression of P38α, the family's most important member, in pancreatic ductal adenocarcinoma (PDAC) and its association with clinicoathological parameters and patients' prognosis. Materials and methods: We retrospectively analyzed 152 patients who underwent surgery and were pathologically diagnosed with PDAC from September 2013 to September 2015. We used immunohistochemistry to detect P38α expression in tumor and adjacent normal tissues. The significance of the association between P38α and clinicopathological parameters was evaluated using the χ² test and t tests. The Kaplan-Meier method was used to assess the association between P38α expression and preoperative carbohydrate antigen 19-9 (CA19-9) levels and patients' overall survival. The Cox regression model was used to analyze the association between clinicopathological parameters, P38α and preoperative CA19-9 levels, and prognosis. Statistical significance was defined as P < 0.05. Results: P38α was expressed in 63.16% tumor tissues of PDAC, which was significantly higher compared with the adjacent normal tissues (26.32%, P < 0.001). High expression of P38α was associated with patients' histological grade (P = 0.013), lymphatic metastasis (P = 0.025) and TNM stage (P = 0.048). The median survival time of the P38α-high group was 9.2 months, which was shorter compared with that of the P38α-low group (17.3 months, P = 0.011). The median survival time of the CA19-9 > 43.63 group was 11.1 months shorter than that of the CA19-9 < 43.63 group (24.8 months, P < 0.001). The Cox regression model revealed that age (P = 0.003), lymphatic invasion (P = 0.015), TNM stage (P = 0.003), histological grade (P < 0.001), preoperative CA19-9 (P = 0.049), and P38α expression (P = 0.008) were statistically significant independent risk factors affecting prognosis. Specifically, overall survival was 28.4 months in the P38α-low and CA19-9 < 43.63 groups, 16.3 months in the P38α-high or CA19-9 > 43.63 groups, and 9.7 months in the P38α-high and CA19-9 > 43.63 groups (P < 0.001). Conclusions: High expression of P38α was significantly associated with histological grade, lymphatic metastasis, TNM stage and prognosis in patients with PDAC. P38α and preoperative CA19-9 levels were independent risk factors affecting the prognosis of PDAC patients. High expression of p38α and preoperative carbohydrate antigen 19-9 indicate poor prognosis in patients with PDAC.

Prognostic Significance of Cytokeratin 19 Expression in Pancreatic Neuroendocrine Tumor: A Meta-Analysis

Clinical Significance of the Preoperative Main Pancreatic Duct Dilation and Neutrophil-to-lymphocyte Ratio in Pancreatic Neuroendocrine Tumors (pnets) of the Head after Curative Resection

A Prognostic Nomogram in Patients with Distant Metastasis of Pancreatic Neuroendocrine Tumors: a Population-Based Study.

Expression of CK19 and KIT in Resectable Pancreatic Neuroendocrine Tumors.

Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors

Prognostic Value of Cytokeratin 19 in Hepatocellular Carcinoma: A Meta-Analysis.

Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

How Reliable is the Ki-67 Cytological Index in Grading Pancreatic Neuroendocrine Tumors? A Meta-Analysis

High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma

Prognostic Factors and Survival in Patients with Neuroendocrine Tumors of the Pancreas

Correlations of CT features,pathological findings and expression of Ki-67 in cystic-solid pancreatic neuroendocrine tumors

Carbohydrate Antigen 19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors.

The Prognostic Value of Multidetector CT Features in Predicting Overall Survival Outcomes in Patients with Pancreatic Neuroendocrine Tumors.

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Prognostic Significance of CDKN1B (p27) Expression in Gastroenteropancreatic Neuroendocrine Tumors

Analysis of Risk Factors Affecting the Prognosis of Pancreatic Neuroendocrine Tumors

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors

Glypican-3 and Cytokeratin-19 Expression in Pancreatic Cancer in a Canadian Population

Glypican-3 and Krt19 Are Markers Associating with Metastasis and Poor Prognosis of Pancreatic Ductal Adenocarcinoma